Recombinant Ralstonia pickettii Phosphoserine aminotransferase (serC)

What is Ralstonia pickettii and why is it significant for researchers?

Ralstonia pickettii is a Gram-negative, non-fermentative, aerobic rod bacterium previously classified as Pseudomonas pickettii and later Burkholderia pickettii before being reclassified as Ralstonia pickettii in 1995. While generally considered to have low virulence, it has significant research interest due to its ability to cause bloodstream infections in immunocompromised or critically ill patients, particularly when it contaminates medical products. R. pickettii can bypass sterile filters with pore sizes of 0.2 μm used in pharmaceutical processes, which contributes to its presence in sterile products . The organism has been implicated in nosocomial outbreaks, making it relevant for both clinical microbiology and industrial contamination research contexts .

What is phosphoserine aminotransferase (serC) and what role does it play in R. pickettii metabolism?

Phosphoserine aminotransferase (PSAT), encoded by the serC gene, is a critical enzyme in the phosphorylated pathway of L-serine biosynthesis. While the available search results primarily discuss human PSAT isoforms rather than R. pickettii specifically, we can infer that R. pickettii PSAT functions similarly to other bacterial PSATs. The enzyme catalyzes the conversion of 3-phosphohydroxypyruvate to L-3-phosphoserine using glutamate as an amino donor, representing the second step in the three-step phosphorylated serine biosynthetic pathway. This pathway is essential for amino acid metabolism and cellular function in bacteria, including R. pickettii, as serine serves as a precursor for various biomolecules including proteins, phospholipids, and other amino acids .

How does R. pickettii phosphoserine aminotransferase compare structurally and functionally to human PSAT isoforms?

Human PSAT exists in two isoforms (HsPSATα and HsPSATβ) resulting from alternative splicing. HsPSATα consists of 324 amino acids (35.2 kDa), while HsPSATβ has 370 amino acids (40 kDa). The key structural difference is that PSATα lacks 46 amino acids between Val290 and Ser337 of PSATβ, which is encoded by the entire exon 8 (138 bp). Functionally, GST-PSATβ shows approximately 6.8 times higher enzyme activity than GST-PSATα when expressed in E. coli .

What are the recommended methods for isolating and identifying R. pickettii for subsequent serC gene cloning?

For reliable isolation and identification of R. pickettii prior to serC gene cloning, a combination of techniques is recommended. Initially, isolation from clinical or environmental samples should be attempted using selective or differential media. Following isolation, a tiered identification approach is advised:

• VITEK 2 system can provide preliminary identification, though it shows 100% sensitivity but only 70.8% specificity when compared to 16S rDNA sequencing .

• PCR using R. pickettii-specific primers targeting a 210 bp fragment provides higher specificity (85.7%) and good sensitivity (85.3%) .

• 16S rDNA sequencing remains the gold standard for definitive identification of R. pickettii isolates .

Once identified, whole genome sequencing can be performed to identify the serC gene for subsequent cloning experiments. When designing primers for serC amplification, researchers should consider the high GC content typical of Ralstonia species and include appropriate restriction sites for downstream cloning applications.

What expression systems are most effective for producing recombinant R. pickettii phosphoserine aminotransferase?

While specific expression data for R. pickettii serC is not provided in the search results, we can draw from general principles of recombinant protein expression and data on human PSAT expression:

Table 1: Comparison of Expression Systems for Recombinant PSAT Production

For most applications, E. coli remains the system of choice, particularly with fusion tags like His6 or GST to aid purification and solubility. Based on the successful expression of human PSAT in E. coli as a GST fusion protein, a similar approach would likely be effective for R. pickettii PSAT .

What are the critical parameters that affect the expression level and solubility of recombinant R. pickettii serC protein?

Several parameters critically influence the expression and solubility of recombinant proteins, including R. pickettii PSAT:

• Expression temperature: Lower temperatures (15-25°C) often improve protein folding and solubility at the expense of expression rate.

• Induction conditions: IPTG concentration for T7-based systems should be optimized; too high concentrations can lead to inclusion body formation.

• Media composition: Enriched media (TB, 2YT) can improve yields but may increase the rate of misfolding; minimal media may reduce growth but improve folding.

• Fusion partners: Solubility-enhancing tags (GST, MBP, SUMO) may dramatically improve solubility. The successful expression of human PSAT as a GST fusion suggests this approach may work well for R. pickettii PSAT .

• Codon optimization: Adaptation of the R. pickettii serC gene to the codon usage of the expression host can significantly improve expression levels.

• Co-expression with chaperones: GroEL/GroES or other chaperone systems can improve folding of challenging proteins.

By systematically optimizing these parameters, researchers can maximize both yield and solubility of recombinant R. pickettii PSAT.

What purification strategy would yield the highest purity and activity of recombinant R. pickettii PSAT?

A multi-step purification strategy is recommended to achieve high purity and preserve activity of recombinant R. pickettii PSAT:

• Affinity chromatography: For His-tagged constructs, immobilized metal affinity chromatography (IMAC) using Ni-NTA or Co-NTA resins; for GST-tagged constructs, glutathione-Sepharose. Based on the successful purification of GST-tagged human PSAT, this approach would likely be effective for R. pickettii PSAT as well .

• Ion exchange chromatography: As a second step to remove contaminants with similar affinity properties but different charge characteristics.

• Size exclusion chromatography: Final polishing step to separate monomeric, properly folded protein from aggregates or degradation products.

Throughout purification, it's essential to maintain conditions that preserve enzyme activity. For PSAT, this typically includes:

• Buffer components: 20-50 mM Tris or phosphate buffer, pH 7.5-8.0

• Stabilizing additives: 100-300 mM NaCl, 5-10% glycerol

• Reducing agents: 1-5 mM DTT or β-mercaptoethanol to maintain free sulfhydryl groups

• Protease inhibitors: During initial extraction steps

• Temperature control: Maintaining 4°C throughout purification

The purification protocol should be validated by assessing enzyme activity at each step to ensure the native conformation and catalytic function are preserved.

What are the established methods for assaying R. pickettii PSAT activity and kinetic parameters?

While specific assays for R. pickettii PSAT are not detailed in the search results, standard approaches for PSAT activity determination can be applied:

Direct Spectrophotometric Assay:
Monitor the conversion of 3-phosphohydroxypyruvate to L-3-phosphoserine coupled with the conversion of glutamate to α-ketoglutarate by measuring the decrease in absorbance at 340 nm when using NADH-dependent glutamate dehydrogenase as a coupling enzyme.

Coupled Enzyme Assay:
In this system, PSAT activity is coupled to the next enzyme in the pathway (phosphoserine phosphatase) and the resulting serine is detected via a colorimetric or fluorometric assay.

For kinetic parameter determination, initial velocity measurements should be conducted across varying concentrations of both substrates (3-phosphohydroxypyruvate and glutamate) to determine Km, Vmax, and kcat values. Temperature and pH optima should also be determined by measuring activity across appropriate ranges (typically pH 6.0-9.0 and 25-45°C).

Based on the characterized human PSAT, researchers might expect R. pickettii PSAT to show PLP-dependence and potentially distinct kinetic properties reflecting its bacterial origin .

What structural and functional analyses would provide the most insight into R. pickettii PSAT mechanism?

To elucidate the structure-function relationship of R. pickettii PSAT, several complementary approaches are recommended:

• X-ray crystallography or cryo-EM: To determine the three-dimensional structure, active site architecture, and PLP binding mode. This would enable comparison with other bacterial and human PSAT structures.

• Site-directed mutagenesis: Targeting predicted catalytic residues based on sequence alignment with characterized PSATs to verify their roles in substrate binding and catalysis.

• Enzyme kinetics with substrate analogues: To probe substrate specificity and identify potential inhibitors.

• Thermal shift assays: To evaluate stability under various conditions and identify stabilizing ligands or buffer components.

• Circular dichroism spectroscopy: To analyze secondary structure content and thermal stability.

• Mass spectrometry: For accurate molecular weight determination and identification of any post-translational modifications.

• Isothermal titration calorimetry: To determine binding constants for substrates and cofactors.

Comparative analysis with human PSAT isoforms would be particularly valuable, given the known structural and functional differences between human PSATα and PSATβ. The human PSATβ isoform has 6.8 times higher activity than PSATα, and understanding the structural basis for this difference could provide insights relevant to bacterial PSAT enzymes as well .

How can recombinant R. pickettii PSAT be utilized in comparative studies with pathogenic and non-pathogenic bacterial species?

Recombinant R. pickettii PSAT offers a valuable tool for comparative studies across bacterial species, with potential applications including:

• Evolutionary analysis: Comparing PSAT sequences and structures across different bacterial lineages, including closely related species like R. mannitolilytica and R. insidiosa, can provide insights into evolutionary relationships and adaptations .

• Functional comparison: Assessing enzymatic properties (specificity, kinetics, stability) of PSATs from pathogenic versus non-pathogenic bacteria may reveal adaptations related to pathogenicity.

• Metabolic pathway analysis: Comparing the regulation and integration of serine biosynthesis pathways across species can illuminate differences in metabolic network organization.

• Cross-species complementation studies: Similar to how human PSAT can rescue S. cerevisiae deletion mutants, R. pickettii PSAT could be tested for its ability to complement serC mutations in other bacterial species .

• Structural biology: Comparative structural analysis of PSATs from different species can identify conserved and variable regions that might be exploited for species-specific inhibitor design.

Such comparative studies could be particularly valuable given R. pickettii's unusual ability to cause infections in clinical settings despite its generally low virulence, potentially revealing metabolic adaptations that contribute to its opportunistic pathogenicity .

What insights could genomic analysis provide about serC gene regulation and expression in clinical versus environmental R. pickettii isolates?

Genomic analysis of the serC gene in R. pickettii could reveal important regulatory adaptations between clinical and environmental isolates:

• Promoter region analysis: Comparing promoter sequences between clinical and environmental isolates might reveal mutations or regulatory element variations that affect expression levels.

• Transcriptomic profiling: RNA-seq analysis under various conditions (different nutrient sources, stress conditions, host-mimicking environments) could identify differential expression patterns.

• Epigenetic regulation: Methylation patterns in the serC gene and its regulatory regions might differ between clinical and environmental isolates, potentially affecting expression.

• Genetic context analysis: The genomic neighborhood of serC might contain different mobile genetic elements or regulatory genes in clinical versus environmental isolates.

Such analysis would be particularly valuable in the context of whole-genome sequencing data from clinical isolates, such as those described in the bloodstream infection investigations. Core genome multilocus sequence typing (cgMLST) has already been applied to investigate relationships between clinical R. pickettii isolates, and similar approaches could be extended to specifically examine serC gene variations .

What are the potential applications of R. pickettii PSAT inhibitors in controlling bacterial contamination in medical products?

Given R. pickettii's ability to contaminate medical products and cause bloodstream infections, PSAT inhibitors could offer novel approaches to contamination control:

• Targeted antimicrobial development: PSAT inhibitors could selectively target R. pickettii in pharmaceutical manufacturing processes without affecting beneficial microorganisms.

• Biofilm prevention: If PSAT activity is linked to biofilm formation capabilities, inhibitors could potentially reduce R. pickettii's ability to form biofilms in water systems and manufacturing equipment.

• Synergistic treatments: PSAT inhibitors could potentially sensitize R. pickettii to conventional antimicrobials or sterilization procedures by disrupting metabolic pathways.

• Preservative development: Selective PSAT inhibitors could serve as preservatives in liquid medical products known to be vulnerable to R. pickettii contamination.

• Biomarker applications: Detection of PSAT or serC could be developed into rapid diagnostic tools for identifying R. pickettii contamination in medical products.

R. pickettii's ability to bypass 0.2 μm sterile filters used in pharmaceutical processes makes it particularly challenging to eliminate through conventional sterilization methods . Enzyme-targeted approaches could provide complementary strategies to address this persistent contamination issue.

What approaches can resolve inclusion body formation during recombinant R. pickettii PSAT expression?

Inclusion body formation is a common challenge in recombinant protein expression. For R. pickettii PSAT, several strategies can be employed:

• Reduce expression temperature: Lowering to 16-20°C can significantly reduce aggregation by slowing protein synthesis and allowing more time for proper folding.

• Optimize induction conditions: Using lower IPTG concentrations (0.1-0.5 mM instead of 1 mM) can reduce expression rate and improve folding.

• Fusion partners: As demonstrated with human PSAT, GST fusion can enhance solubility . Alternative tags like MBP or SUMO may be even more effective for challenging proteins.

• Co-expression with chaperones: GroEL/GroES, DnaK/DnaJ/GrpE, or trigger factor co-expression can significantly improve folding of aggregation-prone proteins.

• Inclusion body refolding: If soluble expression remains challenging, developing a refolding protocol from purified inclusion bodies using gradual dialysis with optimized buffer conditions can be effective.

• Additives in lysis buffer: Including stabilizing agents (10% glycerol, 0.1% Triton X-100, 1M arginine) in the lysis buffer can improve solubility during extraction.

Given the successful expression of human PSAT as a GST fusion protein in E. coli, this approach would likely be effective for R. pickettii PSAT as well, potentially avoiding inclusion body formation altogether .

How can researchers address low or inconsistent enzymatic activity in purified recombinant R. pickettii PSAT preparations?

When facing issues with low or inconsistent enzymatic activity in purified R. pickettii PSAT, consider these methodological approaches:

• Cofactor supplementation: Ensure adequate PLP (pyridoxal-5'-phosphate) concentration in buffers during purification and assays, as PSAT is a PLP-dependent enzyme.

• Reducing conditions maintenance: Include fresh reducing agents (DTT or β-mercaptoethanol) in all buffers to prevent oxidation of catalytic cysteine residues.

• Storage optimization: Test various storage conditions (different buffers, addition of glycerol, flash freezing vs. gradual cooling) to maintain activity.

• Metal ion effects: Investigate the impact of different metal ions on enzyme activity; some may be inhibitory while others could be essential cofactors.

• Protein verification: Confirm protein identity and integrity through mass spectrometry to rule out degradation or truncation.

• Substrate quality: Ensure substrates are fresh and properly prepared; 3-phosphohydroxypyruvate is particularly prone to degradation.

• Assay validation: Validate the assay using a commercial aminotransferase as a positive control to ensure the detection system is functioning properly.

By systematically addressing these factors, researchers can troubleshoot activity issues and establish reliable activity assays for recombinant R. pickettii PSAT.

What experimental design considerations are important when comparing wild-type and mutant variants of R. pickettii PSAT?

When designing experiments to compare wild-type and mutant R. pickettii PSAT variants, several critical considerations should be addressed:

These considerations will ensure robust and meaningful comparisons between PSAT variants, providing insights into structure-function relationships and potentially identifying residues critical for R. pickettii PSAT's unique properties.